Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 2
2012 2
2013 4
2014 6
2015 5
2016 6
2017 9
2018 11
2019 15
2020 11
2021 10
2022 11
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, Yeoh HL, Palmeri M, Ye F, Fan R, Davis EJ, Rapisuwon S, Long GV, Haydon A, Osman I, Mehnert JM, Carlino MS, Sullivan RJ, Menzies AM, Johnson DB. Patrinely JR Jr, et al. Among authors: mehnert jm. JAMA Oncol. 2021 May 1;7(5):744-748. doi: 10.1001/jamaoncol.2021.0051. JAMA Oncol. 2021. PMID: 33764387 Free PMC article.
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. Ott PA, et al. Among authors: mehnert jm. J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13. J Clin Oncol. 2019. PMID: 30557521 Clinical Trial.
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Karz A, et al. Among authors: mehnert jm. Pigment Cell Melanoma Res. 2022 Nov;35(6):554-572. doi: 10.1111/pcmr.13059. Epub 2022 Sep 1. Pigment Cell Melanoma Res. 2022. PMID: 35912544 Free PMC article. Review.
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
Goodman RS, Lawless A, Woodford R, Fa'ak F, Tipirneni A, Patrinely JR, Yeoh HL, Rapisuwon S, Haydon A, Osman I, Mehnert JM, Long GV, Sullivan RJ, Carlino MS, Menzies AM, Johnson DB. Goodman RS, et al. Among authors: mehnert jm. JAMA Netw Open. 2023 Aug 1;6(8):e2327145. doi: 10.1001/jamanetworkopen.2023.27145. JAMA Netw Open. 2023. PMID: 37535354 Free PMC article.
Autophagy, Metabolism, and Cancer.
White E, Mehnert JM, Chan CS. White E, et al. Among authors: mehnert jm. Clin Cancer Res. 2015 Nov 15;21(22):5037-46. doi: 10.1158/1078-0432.CCR-15-0490. Clin Cancer Res. 2015. PMID: 26567363 Free PMC article. Review.
Metastatic Melanoma Treatment in Special Populations.
Miceli M, Boatwright C, Mehnert JM. Miceli M, et al. Among authors: mehnert jm. Cancer J. 2024 Mar-Apr 01;30(2):71-78. doi: 10.1097/PPO.0000000000000701. Cancer J. 2024. PMID: 38527259 Review.
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. Chesney JA, et al. Among authors: mehnert jm. J Immunother Cancer. 2023 May;11(5):e006270. doi: 10.1136/jitc-2022-006270. J Immunother Cancer. 2023. PMID: 37142291 Free PMC article. Clinical Trial.
The "Great Debate" at Melanoma Bridge 2022, Naples, December 1st-3rd, 2022.
Ascierto PA, Blank C, Eggermont AM, Garbe C, Gershenwald JE, Hamid O, Hauschild A, Luke JJ, Mehnert JM, Sosman JA, Tawbi HA, Mandalà M, Testori A, Caracò C, Osman I, Puzanov I. Ascierto PA, et al. Among authors: mehnert jm. J Transl Med. 2023 Apr 18;21(1):265. doi: 10.1186/s12967-023-04100-y. J Transl Med. 2023. PMID: 37072748 Free PMC article.
Oncolytic virus immunotherapy for melanoma.
Dharmadhikari N, Mehnert JM, Kaufman HL. Dharmadhikari N, et al. Among authors: mehnert jm. Curr Treat Options Oncol. 2015 Mar;16(3):326. doi: 10.1007/s11864-014-0326-0. Curr Treat Options Oncol. 2015. PMID: 25777572 Review.
Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR, Mehnert JM. Spencer KR, et al. Among authors: mehnert jm. Cancer Treat Res. 2016;167:295-320. doi: 10.1007/978-3-319-22539-5_13. Cancer Treat Res. 2016. PMID: 26601869 Review.
92 results